These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24166148)

  • 1. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
    Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
    Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
    Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
    J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
    Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
    Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
    Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
    Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
    Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
    Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
    Oda K
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
    Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.